Goldman Sachs Downgrades Halozyme to Sell
HALO faces a post-2030 royalty cliff; Goldman Sachs cuts rating to Sell with $56 target, citing long-term revenue risks.
/ 443 items
#Healthcare↓
Goldman Sachs Initiates Sell Rating on MBX Biosciences
Goldman Sachs starts coverage of MBX Biosciences with a Sell rating and $18 price target, citing cautious outlook ahead of key trial data in 2026.
Needham Starts Coverage on Solid Biosciences with Buy Rating
Needham initiates Buy on Solid Biosciences with $16 target, highlighting potential of SGT-003 gene therapy amid concerns over Sarepta’s Elevidys safety.
Axogen Stock Soars on FDA Approval for Nerve Repair Treatment
Axogen shares jumped 7% in premarket trading after FDA approved its Avance nerve repair treatment for adults and children, strengthening its market position.
Goldman Sachs Upgrades Taysha Gene Therapies on Rett Syndrome Potential
Goldman Sachs upgrades Taysha Gene Therapies to Buy with an $11 target, citing strong confidence in the company’s Rett syndrome program and REVEAL study expectations.
Stifel Bullish on Foghorn Therapeutics Stock
Stifel starts Foghorn Therapeutics coverage with Buy rating and $12 target. Lead drug FHD-909 partnership with Eli Lilly expected to launch in 2030 with strong sales potential.